POSSIBILITIES TO APPLY PROGESTERONE RECEPTOR SELECTIVE MODULATORS IN WOMEN OF REPRODUCTIVE AGE WITH UTERINE MYOMA
| Autor: | G. E. Chernukha, M. R. Dumanovskaya, G. I. Tabeeva |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Медицинский совет, Vol 0, Iss 12, Pp 126-130 (2016) |
| Druh dokumentu: | article |
| ISSN: | 2079-701X 2658-5790 |
| DOI: | 10.21518/2079-701X-2016-12-126-130 |
| Popis: | Uterine myoma is the most common benign monoclonal tumor. The frequency of uterine myoma is 20–35% in women of reproductive age and reaches 70% after the age of 50. Modern strategy of treatment of uterine myomas are largely individualized and depends on the patient’s age, her desire to preserve reproductive function, as well as the size, location, nodes growth rate, hormone therapy possibility. In recent years more and more articles have been published about the successful use of the progesterone receptor selective modulator progesterone ulipristal acetate (UPA) for the treatment of uterine myoma. It is important to note that the interest in the problem of uterine myoma therapy by progesterone receptor selective modulators is not only associated with their inhibiting effect on the growth and size of uterine myoma, but with the effect on the endometrium, the mechanisms of occurrence of amenorrhea and anovulation without reducing endogenous secretion of estrogen. Drug therapy gives a possibility to postpone or to avoid surgical treatment. In this respect long-term intermittent courses of UPA therapy are currently regarded as the most promising. They allow you expanding the possibilities of conservative treatment of uterine myoma, providing a regression of symptoms of the disease and maintaining the effect after completion of therapy. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|